

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Tignor Michael Brent</u> <hr/> (Last) (First) (Middle) <u>C/O BALCHEM CORPORATION</u> <u>52 SUNRISE PARK ROAD</u> <hr/> (Street) <u>NEW HAMPTON NY 10958</u> <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>02/10/2022</u>	3. Issuer Name and Ticker or Trading Symbol <u>BALCHEM CORP [BCPC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Human Resources Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock⁽¹⁾</u>	<u>4,654</u>	<u>D</u>	
<u>Common Stock⁽²⁾</u>	<u>1,790</u>	<u>D</u>	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	02/21/2018 ⁽³⁾	02/21/2027	Common Stock	8,400	\$85.4	D	
Employee Stock Option (right to buy)	02/15/2019 ⁽³⁾	02/15/2028	Common Stock	2,800	\$74.57	D	
Employee Stock Option (right to buy)	02/13/2020 ⁽³⁾	02/13/2029	Common Stock	3,100	\$84.09	D	
Employee Stock Option (right to buy)	02/13/2021 ⁽³⁾	02/13/2030	Common Stock	2,800	\$111.94	D	
Employee Stock Option (right to buy)	02/11/2022 ⁽³⁾	02/11/2031	Common Stock	2,200	\$119.13	D	
Employee Stock Option (right to buy)	02/10/2023 ⁽³⁾	02/10/2032	Common Stock	2,100	\$138.07	D	

Explanation of Responses:

- Ownership consists of 886 shares held in Reporting Person's Company 401(k)/profit sharing plan account and 3,768 shares held directly
- Ownership of restricted stock vests in Reporting Person 3 years following the grant dates and is further subject to restrictions on transfer in accordance with the provisions of a Restricted Stock Grant Agreement between the Issuer and the Reporting Person.
- Options vest 20% year 1; 40% year 2; and 40% year 3

/s/ Michael Brent Tignor, by
Attorney in Fact, Travis Larsen

02/17/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.